Prime Psychiatry Introduces Fast-Acting Antidepressant Spravato for Treatment-Resistant Depression
Prime Psychiatry introduces Spravato, a fast-acting antidepressant for treatment-resistant depression, offering hope for rapid improvement of depressive symptoms.
The availability of Spravato offers hope to individuals struggling with treatment-resistant depression, providing a potential breakthrough in rapidly improving depressive symptoms. This announcement highlights the importance of exploring innovative treatment options for mental health conditions, offering new hope to those who have not responded to traditional treatments.